Table 2.
Variable | Progression-free survival | Overall survival | ||||
---|---|---|---|---|---|---|
Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||
P-value | HR (95% CI) | P-value | P-value | HR (95% CI) | P-value | |
Gender (female vs. male) | 0.485 | 0.631 | ||||
Age (≥ 60 vs. < 60 years) | 0.604 | 0.801 | ||||
ECOG score (≥ 2 vs. 0–1) | 0.001 | 0.002 | ||||
Stage (III–IV vs. I–II) | 0.003 | 0.002 | ||||
B symptoms (yes vs. no) | 0.112 | 0.103 | ||||
LDH (elevated vs. normal) | 0.817 | 0.251 | ||||
NKPI (2–4 vs. 0–1) | 0.003 | 0.003 | ||||
Treatment response (non-CR vs. CR) | 0.009 | 0.014 | ||||
PD-L1+ monocytes in blood (≥ 78.2 vs. < 78.2%) | 0.002 | 11.5 (1.3–103.4) | 0.029 | 0.002 | 10.8 (1.3–93.1) | 0.031 |
CI, confidence interval; CR, complete remission; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; LDH, lactate dehydrogenase; NKPI, natural killer/T-cell lymphoma prognostic index.